NYSE:PFEPharmaceuticals
Does Pfizer (PFE) Updated COVID 19 Vaccine Approval Change Its Near Term Outlook?
Pfizer (NYSE:PFE) and BioNTech received U.S. FDA approval for an updated COVID-19 vaccine tailored to a new virus variant, with authorization for use in seniors and at-risk individuals.
The companies began immediate nationwide distribution of the updated vaccine following the FDA decision.
The approval introduces a refreshed product to Pfizer's COVID-19 portfolio that may affect near-term revenue mix and commercial priorities.
To put Pfizer's news in context, consider exploring other...